OBJECTIVES: 17-Hydroxyprogesterone, an intermediary hormone in cortisol synthesis, has been shown to be elevated in premature infants. However, the relationship between levels of ...

February 15, 2007 (San Francisco) — High-dose 17-alpha hydroxyprogesterone in women at risk for preterm labor effectively prevents preterm delivery by inhibiting cervical ripening and by blocking ...

The use of the hormone 17-Hydroxyprogesterone does not reduce the rate of preterm delivery or neonatal complications in twins, study suggests. In a study to be presented February 10 at the Society for ...

One of the more dramatic studies presented at the 23rd Annual Meeting of the Society for Maternal-Fetal Medicine, held February 3-8, 2003 in San Francisco, California, involved the resurrection of an ...

To the Editor: After reading the article by Meis et al. (June 12 issue), 1 we strongly discourage practitioners from using 17 alpha-hydroxyprogesterone caproate in the care of women who have had ...

After a review, the agency concluded there was a possible risk of cancer to those exposed to 17-hydroxyprogesterone caproate in the womb. The European Medicines Agency (EMA) announced on May 17, 2024 ...

HealthDay News — For women with a prior preterm birth, cerclage plus 17α-hydroxyprogesterone caproate is associated with a significant reduction in delivery at less than 24 weeks of gestation compared ...

The U.S. Food and Drug Administration on Thursday formally withdrew its approval of a drug that was meant to prevent preterm births. Pregnant women will no longer have any drug to prevent preterm ...

SAN FRANCISCO (February 10, 2011) — In a study to be presented today at the Society for Maternal-Fetal Medicine's (SMFM) annual meeting, The Pregnancy Meeting ™, in San Francisco, researchers will ...